3 Wall Street Analysts Think Viking Therapeutics Stock Will Roughly Triple Over the Next 12 Months. Here's Why I Think They're Wrong

Viking Therapeutics (VK2735) is entering phase 3 with subcutaneous VK2735 showing up to 14.7% mean weight loss in a 13-week phase 2 study, with phase 3 results expected in the second half of next year—catalyst-driven upside is possible. The article notes bullish analyst targets around ~$100 (implying roughly tripling), but argues that tripling would require near-flawless outcomes, including phase 3 mean weight loss in the ~23%–26% range versus a retatrutide benchmark of 28.3% mean weight loss. It also flags meaningful downside risk if safety/tolerability or efficacy in phase 3 or the year-end maintenance study disappoints.

Analysis

VKTX is trading like a long-dated option on obesity-category disruption, not a normal clinical-stage biotech. That means the market will punish “good” efficacy if it does not also clear the harder commercial hurdle: durable tolerability, low discontinuation, and enough differentiation to win share from entrenched GLP-1 incumbents.

The main winners on a downside surprise are LLY and NVO, because a weaker readout preserves pricing power and lowers the odds of a new challenger forcing promotional spend or payer concessions. The broader loser set is the small-cap obesity basket and XBI, where a VKTX miss would likely compress multiples across pre-revenue names that are being valued on similar endpoint optionality rather than current cash flow.

The near-term tape is more about positioning and implied volatility than fundamentals; the real catalyst path is maintenance data this year and phase 3 efficacy next year. The contrarian miss in consensus is that oral convenience alone does not solve adherence economics if GI burden remains high; if the market is already paying for near-best-in-class results, anything merely competitive can still translate into a sharp de-rate. Falsifier: a clean safety profile plus clearly superior efficacy versus current class leaders; anything below that likely resets expectations by 6-12 months.

Key Decisions for Investors

• Prefer LLY/NVO vs. VKTX into the next obesity-data window; the pair expresses a negative view on binary development risk while keeping exposure to the category’s secular growth.
• If we want biotech beta, favor IBB over XBI; VKTX disappointment would hit the high-duration, pre-revenue end of the market hardest and should leak into XBI more than IBB.
• Use VKTX put spreads, not outright shorts, only on strength or if implied volatility underprices the binary; downside can be discontinuous on tolerability misses, but upside remains large if data are exceptional.
• Do not add risk to VKTX ahead of the maintenance readout unless we get evidence that discontinuation-adjusted efficacy is meaningfully ahead of peers; otherwise treat rallies as sellable.